SCM
SLN

Soleus Capital Management’s Silence Therapeutics SLN Stock Holding History

Soleus Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-260,000
Closed -$4.73M – 103
2024
Q3 		$4.73M Buy
+260,000
New +$4.84M 0.37% 62

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Soleus Capital Management's SLN Position: Q4 2024 in Review

Soleus Capital Management sold out of Silence Therapeutics (SLN) in Q4 2024, closing a stake of 260,000 shares — an estimated $4.73M sold.

Soleus Capital Management first reported a position in SLN in Q3 2024 and held it in 1 quarter. The position peaked at $4.73M in Q3 2024. 65 funds tracked by Wall St. Rank hold SLN as of Q4 2024.

  • Soleus Capital Management reported no remaining Silence Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Soleus Capital Management sold 260,000 Silence Therapeutics shares in Q4 2024, an estimated $4.73M.
  • Soleus Capital Management first reported a position in Silence Therapeutics in Q3 2024 and held it in 1 quarter.
  • Soleus Capital Management's Silence Therapeutics position peaked at $4.73M in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2024.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.